title: [Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization].
abstract: The effect of cyproterone acetate (CPA) and spironolactone (SPL) on the serum androgen concentrations of premenopausal women with symptoms of hyperandrogenism were investigated in a total of 39 women. The observation period was 12 months. CPA was administered according to the Hammerstein regimen: cyproterone acetate (CPA) [Androcur] 100 mg/die 5.-14. day of the cycle; ethinylestradiol (EE) [Progynon C]: 40 mg/die 5.-25. day of the cycle; Spironolactone (SPL) was given in a dosage of 100 mg/die from day 1.-21. of the cycle. During the therapy with CPA a significant decrease of total testosterone (61%), free testosterone (78%), LH (48%) and 17 alpha-Hydroxyprogesterone (72%) was observed; during the medication with spironolacton only a significant decrease of 5 alpha-dihydrotestosterone (81%), which could not be seen during CPA use, was observed. Serum concentrations of total testosterone, free testosterone, LH and 17 alpha-Hydroxyprogesterone remained unchanged. DHA and DHAS did not change during neither medication. Since peripheral androgens were not suppressed by SPL the positive therapeutical effect of SPL can be explained by the antiandrogenic effect at the level of the receptor. A disadvantage of spironolacton is the lack of contraceptive efficacy. In cases where contraindication for oral contraceptives are present SPL can be considered as a good alternative to CPA. The suppressive effect of CPA/EE on total testosterone, LH addition to the antivulatory effect makes it the preferable medication for hyperandrogenemic patients with polycystic changes of the ovaries (PCOD).
authors.affiliation: Abt. für gynäkologische Endokrinologie und Fortpflanzungsmedizin, Universitäts-Frauenklinik Heidelberg.
authors.forename: K
authors.initials: K
authors.lastname: Grunwald
authors.forename: T
authors.initials: T
authors.lastname: Rabe
authors.forename: G
authors.initials: G
authors.lastname: Schlereth
authors.forename: B
authors.initials: B
authors.lastname: Runnebaum
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000728:Androgens / Q000097:blood*; D017373:Cyproterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy; D013148:Spironolactone / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D012739:Gonadal Steroid Hormones; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D017373:Cyproterone Acetate
vernacular_title: Serumhormone vor und unter Therapie mit Cyproteronazetat und Spironolacton bei Patientinnen mit Androgenisierungserscheinungen.